JP2020521000A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020521000A5 JP2020521000A5 JP2020515282A JP2020515282A JP2020521000A5 JP 2020521000 A5 JP2020521000 A5 JP 2020521000A5 JP 2020515282 A JP2020515282 A JP 2020515282A JP 2020515282 A JP2020515282 A JP 2020515282A JP 2020521000 A5 JP2020521000 A5 JP 2020521000A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- polypeptide
- amino acid
- acid sequence
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023010057A JP2023052647A (ja) | 2017-05-23 | 2023-01-26 | 標的治療免疫調節のためのＭＨＣクラスＩｂ分子及びペプチドの組合せ |
| JP2025014951A JP2025072445A (ja) | 2017-05-23 | 2025-01-31 | 標的治療免疫調節のためのＭＨＣクラスＩｂ分子及びペプチドの組合せ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17172444.6 | 2017-05-23 | ||
| EP17172444 | 2017-05-23 | ||
| PCT/EP2018/063100 WO2018215340A1 (en) | 2017-05-23 | 2018-05-18 | Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023010057A Division JP2023052647A (ja) | 2017-05-23 | 2023-01-26 | 標的治療免疫調節のためのＭＨＣクラスＩｂ分子及びペプチドの組合せ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020521000A JP2020521000A (ja) | 2020-07-16 |
| JP2020521000A5 true JP2020521000A5 (enExample) | 2021-02-04 |
Family
ID=58778895
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020515282A Pending JP2020521000A (ja) | 2017-05-23 | 2018-05-18 | 標的治療免疫調節のためのＭＨＣクラスＩｂ分子及びペプチドの組合せ |
| JP2023010057A Pending JP2023052647A (ja) | 2017-05-23 | 2023-01-26 | 標的治療免疫調節のためのＭＨＣクラスＩｂ分子及びペプチドの組合せ |
| JP2025014951A Pending JP2025072445A (ja) | 2017-05-23 | 2025-01-31 | 標的治療免疫調節のためのＭＨＣクラスＩｂ分子及びペプチドの組合せ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023010057A Pending JP2023052647A (ja) | 2017-05-23 | 2023-01-26 | 標的治療免疫調節のためのＭＨＣクラスＩｂ分子及びペプチドの組合せ |
| JP2025014951A Pending JP2025072445A (ja) | 2017-05-23 | 2025-01-31 | 標的治療免疫調節のためのＭＨＣクラスＩｂ分子及びペプチドの組合せ |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20200157175A1 (enExample) |
| EP (1) | EP3630809A1 (enExample) |
| JP (3) | JP2020521000A (enExample) |
| KR (2) | KR102748741B1 (enExample) |
| CN (2) | CN110945019B (enExample) |
| AU (1) | AU2018274545B2 (enExample) |
| CA (1) | CA3063959A1 (enExample) |
| WO (1) | WO2018215340A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112941030B (zh) * | 2021-01-25 | 2023-08-08 | 吉林大学 | 一种抗原特异性Treg及其制备方法和应用 |
| AU2023240382A1 (en) | 2022-03-24 | 2024-11-14 | Julius-Maximilians-Universität Würzburg | Mhc ib-mediated myelin-specific immunosuppression as a novel treatment for multiple sclerosis and mog antibody disease |
| EP4249062A1 (en) | 2022-03-24 | 2023-09-27 | Julius-Maximilians-Universität Würzburg | Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo |
| EP4249506A1 (en) | 2022-03-24 | 2023-09-27 | Julius-Maximilians-Universität Würzburg | Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease |
| EP4499133A1 (en) | 2022-03-24 | 2025-02-05 | Julius-Maximilians-Universität Würzburg | Mhc ib-mediated islet-antigen-specific immunosuppression as a novel treatment for type 1 diabetes |
| WO2025061918A1 (en) | 2023-09-22 | 2025-03-27 | Julius-Maximilians-Universität Würzburg | Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease |
| WO2025061913A1 (en) | 2023-09-22 | 2025-03-27 | Julius-Maximilians-Universität Würzburg | Mhc ib-mediated myelin-specific immunosuppression as a novel treatment for multiple sclerosis and mog antibody disease |
| WO2025061917A1 (en) | 2023-09-22 | 2025-03-27 | Julius-Maximilians-Universität Würzburg | Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4470007B2 (ja) | 1998-02-20 | 2010-06-02 | コミサリア・ア・レネルジー・アトミーク | Ｈｌａ−ｇを発現する、抗癌治療に感受性な腫瘍を選択する方法およびその使用 |
| FR2794977B1 (fr) | 1999-06-18 | 2003-10-31 | Commissariat Energie Atomique | Utilisation de compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau, et leur procede d'obtention |
| US9234174B2 (en) * | 2006-05-12 | 2016-01-12 | Ospedale San Raffaele S.R.L. | Tolerogenic dendritic cells, method for their production and uses therof |
| CN101678090B (zh) * | 2007-03-07 | 2012-04-11 | 乌第有限合伙公司 | 用于预防和治疗自身免疫病的组合物和方法 |
| WO2009100135A2 (en) * | 2008-02-04 | 2009-08-13 | Medical College Georgia Research Institute, Inc. | Hla-g compositions and methods of use thereof |
| EP2184297A1 (en) * | 2008-11-07 | 2010-05-12 | Hla-G Technologies | HLA-G polypeptides and pharmaceutical uses thereof |
| EP2699593B2 (en) * | 2011-04-20 | 2020-11-04 | University of Washington Through Its Center for Commercialization | Beta-2 microglobulin-deficient cells |
| WO2014052545A2 (en) * | 2012-09-28 | 2014-04-03 | Dana-Farber Cancer Institute, Inc. | Targeted expansion of qa-1-peptide-specific regulatory cd8 t cells to ameliorate arthritis |
| EP2730588A1 (en) * | 2012-11-12 | 2014-05-14 | Intelectys | Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof |
| CA2959821C (en) * | 2014-10-24 | 2024-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for inducing phagocytosis of MHC class I positive cells and for overcoming resistance to anti-CD47 agents/SIRPA |
-
2018
- 2018-05-18 KR KR1020197038051A patent/KR102748741B1/ko active Active
- 2018-05-18 KR KR1020247042945A patent/KR20250007053A/ko active Pending
- 2018-05-18 CA CA3063959A patent/CA3063959A1/en active Pending
- 2018-05-18 CN CN201880048884.4A patent/CN110945019B/zh active Active
- 2018-05-18 CN CN202411123693.3A patent/CN119185534A/zh active Pending
- 2018-05-18 JP JP2020515282A patent/JP2020521000A/ja active Pending
- 2018-05-18 WO PCT/EP2018/063100 patent/WO2018215340A1/en not_active Ceased
- 2018-05-18 US US16/615,188 patent/US20200157175A1/en not_active Abandoned
- 2018-05-18 AU AU2018274545A patent/AU2018274545B2/en active Active
- 2018-05-18 EP EP18725526.0A patent/EP3630809A1/en active Pending
-
2023
- 2023-01-26 JP JP2023010057A patent/JP2023052647A/ja active Pending
- 2023-06-05 US US18/329,267 patent/US20230416338A1/en active Pending
-
2025
- 2025-01-31 JP JP2025014951A patent/JP2025072445A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020521000A5 (enExample) | ||
| EP1594896B1 (en) | Modified soluble t cell receptor | |
| AU2019257362B2 (en) | Erythrocyte-binding therapeutics | |
| RU2645256C2 (ru) | Высокостабильный т-клеточный рецептор и способ его получения и применения | |
| AU2003271904B2 (en) | Single chain recombinant T cell receptors | |
| JP2020511949A5 (enExample) | ||
| JP2017519491A5 (enExample) | ||
| US10316087B2 (en) | Soluble and stable heterodimeric TCR | |
| US20240190969A1 (en) | Specific binding molecules | |
| JP2019515653A5 (enExample) | ||
| CN106459177A (zh) | 高亲和力ny‑eso t细胞受体 | |
| US11851469B2 (en) | Soluble heterodimeric T cell receptor, and preparation method and use thereof | |
| WO2021170117A1 (zh) | 一种识别afp抗原短肽的t细胞受体及其编码序列 | |
| WO2019228032A1 (zh) | 磷酸化多肽抗原疫苗及其制备方法和应用 | |
| WO2021139699A1 (zh) | 一种识别afp的t细胞受体及其编码序列 | |
| WO2021170116A1 (zh) | 一种识别afp的t细胞受体 | |
| CN116836260A (zh) | 一种识别mage-a4的t细胞受体及其编码序列和应用 | |
| CN117106059A (zh) | 一种识别mage的t细胞受体及其应用 | |
| JP2021045150A5 (enExample) | ||
| JP7377604B2 (ja) | アネキシンのコアドメイン、並びに抗原送達及びワクチン接種におけるその使用 | |
| CN111164099A (zh) | 抗原蛋白及其方法 | |
| WO2022262835A1 (zh) | 一种识别afp抗原的tcr及其编码序列 | |
| HK1089452A (en) | Modified soluble t cell receptor |